Obesity: A Market in Need of a Solution


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 159. Categories: , .

Product Description

With a potentially open market for drugs to treat obesity and related diseases, pharmaceutical companies not only have to provide a pharmacological solution but also address the life-style issues associated with the disease and develop safe products that are effective and have few side effects.
Take a growing patient population that is searching for a quick therapeutic fix. Add a dash of marketed drugs that have only moderate success profiles. Temper this with some skepticism amid highly publicized product withdrawals. Then stir in a regulatory agency that is considering changing its development guidelines. This becomes a recipe for a market with unmet needs.
Epidemiological studies have shown that the prevalence for obesity has increased at an alarming rate in the United States and the majority of European countries in the last 10 years. The prevalence of obesity in adults is 10% to 25% in most countries of Western Europe and 20% to 25% in some countries in the Americas. Today, an estimated 300 million people around the world are obese, and prospective studies predict that this number will continue to climb. In addition to the epidemic of obesity in the adult population, the prevalence of obesity in children is dramatically increasing. In 1999, 13% of children 6 years to 11 years old and 14% of adolescents between 12 and 19 years of age in the United States were overweight. This prevalence has nearly tripled for adolescents in the past two decades. Overweight adolescents have a 70% chance of becoming overweight or obese adults. This increases to 80% if one or both parents are overweight or obese…

Obesity Facts
The Obesity Market: 2003-2013
Patient Satisfaction with Weight Loss Drugs
Leading Disease Research Funding
Sound Bites from the Field

Experts on this Topic
Robert Anfield, M.D.
Medical Director and VP, UnumProvident Corp., Chattanooga, Tenn.; UnumProvident is a provider of group and individual disability income protection insurance. For more information, visit
Dominic P. Behan, Ph.D. Cofounder, Director, Senior VP, and Chief Scientific Officer, Arena Pharmaceuticals Inc., San Diego; Arena Pharmaceuticals is a biopharmaceutical company focusing on the discovery, development, and commercialization of drugs in four major therapeutic areas: metabolic, cardiovascular, inflammatory, and central nervous system diseases. For more information, visit
Rochelle Ellis. Senior Consultant, Navigant Consulting Inc., San Mateo, Calif.; Navigant Consulting is a specialized independent consulting firm providing litigation, financial, restructuring, strategic, and operational consulting services, and legal counsel. For more information, visit
Eric A. Finkelstein. Associate Director, Center for Health Promotion Economics, RTI International, Research Triangle Park, N.C.; RTI’s mission is to improve the human condition through objective, multidisciplinary research, development, and technical services, setting the standard for scientific and professional excellence. For more information, visit
Jonathan B. Hauptman, M.D. Director, Metabolic Program, Roche, Nutley, N.J.; Roche is one of the world’s innovation-driven healthcare groups. For more information, visit
Adam Noah. Research Analyst, Healthcare, Granite Financial Group, San Diego; Granite Financial Group is a full-service investment bank and institutional broker. For more information, visit
Rebecca A. Taub, M.D. VP, Research, Metabolic Diseases, Roche, Nutley, N.J.; Roche is one of the world’s innovation-driven healthcare groups. For more information, visit
Carol Waldman, Ph.D. Senior VP, NOP World Health, East Hanover, N.J.; NOP World Health is a leading provider of primary research to the global healthcare industry. For more information, visit
Christian Weyer. Senior Director, Clinical Research, Amylin Pharmaceuticals Inc., San Diego; Amylin is a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with metabolic diseases. For more information, visit
Donny Wong, Ph.D. Analyst, Decision Resources Inc., Waltham, Mass.; Decision Resources provides market-research publications, advisory services, andconsulting. For more information, visit